ストックスクリーナーアプリを入手
1.36
0.73%
-0.01
前日終値:
$1.37
開ける：
$1.37
24時間の取引高:
363.19K
Relative Volume:
4.67
時価総額：
$6.10M
収益：
$960.60K
当期純損益:
$-7.10M
株価収益率:
-0.1799
EPS:
-7.56
ネットキャッシュフロー:
$-8.00M
1週間 パフォーマンス:
-20.00%
1か月 パフォーマンス:
-28.80%
6か月 パフォーマンス:
-52.94%
1年 パフォーマンス:
-48.68%
1日の値動き範囲:
$1.3205
$1.52
1週間の範囲:
$1.31
$1.77
52週間の値動き範囲:
$1.31
$14.83
Soligenix Inc Stock (SNGX) Company Profile
SNGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.36 | 6.10M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-28 | ダウングレード | Dawson James | Buy → Neutral |
| 2018-01-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 繰り返されました | Maxim Group | Buy |
| 2017-07-17 | 開始されました | H.C. Wainwright | Buy |
Soligenix Inc (SNGX) 最新ニュース
Soligenix Inc. Advances in Treatment for Behçet’s Disease with SGX945 - citybuzz -
Soligenix (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease - The Globe and Mail
Behcet's Disease Market Growth to Accelerate in Forecast Period - openPR.com
Cutaneous T-cell Lymphoma Market on Track for Major Expansion by 2034, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand Pharma - Barchart.com
True North Commercial REIT Announces June 2025 Distribution - The Globe and Mail
Soligenix Inc. (NASDAQ: SNGX) Makes Strides in Rare Disease Treatments with Upcoming Clinical Trial Results - citybuzz -
Silicon Valley - FinancialContent
Soligenix (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL - Barchart.com
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise - GuruFocus
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials | SNGX Stock News - GuruFocus
Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewswire
Soligenix Inc. (SNGX) Showcases Promising HyBryte Results in CTCL Treatment Through New Podcast - citybuzz -
Soligenix (NASDAQ: SNGX) Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim - Barchart.com
Soligenix (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics - Barchart.com
Vaccine Contract Manufacturing Market Is Booming Worldwide | - openPR.com
Galaxy Digital Inc. Announces Public Offering of Common Stock - The Globe and Mail
Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results In Rare Cancer Trial - Barchart.com
Stocks in play: Brookfield Corporation - The Globe and Mail
Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial - The Globe and Mail
Chemung Financial Corporation Announces Quarterly Dividend - The Globe and Mail
Soligenix’s HyBryte Shows Promise in Rare Cancer Treatment - citybuzz -
Soligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results - The Globe and Mail
/R E P E A T -- Scotiabank to Announce Second Quarter 2025 Results/ - The Globe and Mail
Public market insider selling at Sprott (SII) - The Globe and Mail
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent
Zacks Small Cap Predicts Reduced Earnings for Soligenix - Defense World
Zacks Research Issues Business Update as Soligenix (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial - The Globe and Mail
Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL… - MSN
Soligenix Reports Q1 2025 Financial Results and Milestones - TipRanks
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte in CTCL - Research Tree
Contrasting Schrödinger (NASDAQ:SDGR) and Soligenix (NASDAQ:SNGX) - Defense World
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - Nasdaq
Soligenix Announces Recent Accomplishments And First Quarter 202 - GuruFocus
Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast Episode - The Globe and Mail
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times
Geode Capital Management LLC Has $71,000 Stake in Soligenix, Inc. (NASDAQ:SNGX) - Defense World
Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response - FinancialContent
Soligenix (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer - Barchart.com
Soligenix (SNGX) Projected to Post Quarterly Earnings on Friday - Defense World
Soligenix (NASDAQ: SNGX) Moves Forward To Strengthen The Case For HyBryte(TM) - Barchart.com
Soligenix (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM) - The Globe and Mail
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Soligenix reports positive results in skin cancer treatment trial By Investing.com - Investing.com India
Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc. - Yahoo Finance
Soligenix reports positive results in skin cancer treatment trial - Investing.com Australia
Soligenix Inc (SNGX) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.70%
大文字化:
|
ボリューム (24 時間):